STRHÁRSKY, Tomáš, Dominika PINDJAKOVA, Jiří KOS, Lucia VRABLOVA, Pavel ŠMAK, Hana MICHNOVA, Tomáš GONĚC, Jan HOŠEK, Michal ORAVEC, Izabela JENDRZEJEWSKA, Alois ČÍŽEK and Josef JAMPILEK. Trifluoromethylcinnamanilide Michael Acceptors for Treatment of Resistant Bacterial Infections. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2022, vol. 23, No 23, p. 1-22. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms232315090.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Trifluoromethylcinnamanilide Michael Acceptors for Treatment of Resistant Bacterial Infections
Authors STRHÁRSKY, Tomáš (703 Slovakia, belonging to the institution), Dominika PINDJAKOVA, Jiří KOS (203 Czech Republic, guarantor, belonging to the institution), Lucia VRABLOVA, Pavel ŠMAK (203 Czech Republic, belonging to the institution), Hana MICHNOVA, Tomáš GONĚC (203 Czech Republic, belonging to the institution), Jan HOŠEK (203 Czech Republic), Michal ORAVEC, Izabela JENDRZEJEWSKA, Alois ČÍŽEK (203 Czech Republic) and Josef JAMPILEK.
Edition International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2022, 1422-0067.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.600
RIV identification code RIV/00216224:14110/22:00127694
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/ijms232315090
UT WoS 000897240400001
Keywords in English cinnamamides; Michael acceptors; antimicrobial activity; cytotoxicity; lipophilicity; structure-activity relationships; docking study
Tags 14110512, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 30/1/2023 12:13.
Abstract
A series of thirty-two anilides of 3-(trifluoromethyl)cinnamic acid (series 1) and 4-(trifluoromethyl)cinnamic acid (series 2) was prepared by microwave-assisted synthesis. All the compounds were tested against reference strains Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 and resistant clinical isolates of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant E. faecalis (VRE). All the compounds were evaluated in vitro against Mycobacterium smegmatis ATCC 700084 and M. marinum CAMP 5644. (2E)-3-[3-(Trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]prop-2-enamide (1j), (2E)-N-(3,5-dichlorophenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide (1o) and (2E)-N-[3-(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)-phenyl]prop-2-enamide (2i), (2E)-N-[3,5-bis(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)phenyl]-prop-2-enamide (2p) showed antistaphylococcal (MICs/MBCs 0.15-5.57 mu M) as well as anti-enterococcal (MICs/MBCs 2.34-44.5 mu M) activity. The growth of M. marinum was strongly inhibited by compounds 1j and 2p in a MIC range from 0.29 to 2.34 mu M, while all the agents of series 1 showed activity against M. smegnatis (MICs ranged from 9.36 to 51.7 mu M). The performed docking study demonstrated the ability of the compounds to bind to the active site of the mycobacterial enzyme InhA. The compounds had a significant effect on the inhibition of bacterial respiration, as demonstrated by the MTT assay. The compounds showed not only bacteriostatic activity but also bactericidal activity. Preliminary in vitro cytotoxicity screening was assessed using the human monocytic leukemia cell line THP-1 and, except for compound 2p, all effective agents did show insignificant cytotoxic effect. Compound 2p is an interesting anti-invasive agent with dual (cytotoxic and antibacterial) activity, while compounds 1j and 1o are the most interesting purely antibacterial compounds within the prepared molecules.
Links
90123, large research infrastructuresName: CzeCOS III
PrintDisplayed: 20/7/2024 15:31